Sort by
Items per page

Send to

Choose Destination

Best matches for ROSUVASTATIN/TU:

Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile. Vrkić Kirhmajer M et al. Basic Clin Pharmacol Toxicol. (2018)

Rosuvastatin: Beyond the cholesterol-lowering effect. Cortese F et al. Pharmacol Res. (2016)

Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. Yang YJ et al. Clin Ther. (2017)

Search results

Items: 1 to 20 of 455


Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.

Boulate G, Amazit L, Naman A, Seck A, Paci A, Lombes A, Pussard E, Baudin E, Lombes M, Hescot S.

Int J Oncol. 2019 Jun;54(6):2149-2156. doi: 10.3892/ijo.2019.4770. Epub 2019 Apr 3.


Chylomicron mimicking nanocolloidal carriers of rosuvastatin calcium for lymphatic drug targeting and management of hyperlipidemia.

Beg S, Alam MN, Ahmad FJ, Singh B.

Colloids Surf B Biointerfaces. 2019 May 1;177:541-549. doi: 10.1016/j.colsurfb.2019.02.039. Epub 2019 Feb 20.


Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model.

Cho O, Jang YJ, Park KY, Heo TH.

Pharmacol Rep. 2019 Apr;71(2):266-271. doi: 10.1016/j.pharep.2018.12.005. Epub 2018 Dec 14.


Stroke in a young man: a late complication of radiation therapy.

Jiang Z, Elkind M, Lucky M, Fekete Z.

BMJ Case Rep. 2019 Feb 22;12(2). pii: e228029. doi: 10.1136/bcr-2018-228029.


Statins Can Lead to Acute Hemolysis.

Moghadasi M, Maghsoomi Z.

Cardiovasc Hematol Agents Med Chem. 2018;16(2):123. doi: 10.2174/1871525716666180928121652.


Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.

Ramakumari N, Indumathi B, Katkam SK, Kutala VK.

Indian Heart J. 2018 Dec;70 Suppl 3:S120-S125. doi: 10.1016/j.ihj.2018.07.009. Epub 2018 Aug 10.


'Temporary Plasticiser': A novel solution to fabricate 3D printed patient-centred cardiovascular 'Polypill' architectures.

Pereira BC, Isreb A, Forbes RT, Dores F, Habashy R, Petit JB, Alhnan MA, Oga EF.

Eur J Pharm Biopharm. 2019 Feb;135:94-103. doi: 10.1016/j.ejpb.2018.12.009. Epub 2018 Dec 21.


Rosuvastatin attenuates piroxicam-mediated gastric ulceration and hepato-renal toxicity in rats.

Abdeen A, Aboubakr M, Elgazzar D, Abdo M, Abdelkader A, Ibrahim S, Elkomy A.

Biomed Pharmacother. 2019 Feb;110:895-905. doi: 10.1016/j.biopha.2018.11.004. Epub 2018 Dec 17.


Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation.

Shirahama R, Ono T, Nagamatsu S, Sueta D, Takashio S, Chitose T, Fujisue K, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Hori M, Harada-Shiba M, Kajiwara I, Ogawa H, Tsujita K.

Intern Med. 2018;57(24):3551-3557. doi: 10.2169/internalmedicine.1060-18. Epub 2018 Dec 15.


Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.

Yebyo HG, Aschmann HE, Puhan MA.

Ann Intern Med. 2019 Jan 1;170(1):1-10. doi: 10.7326/M18-1279. Epub 2018 Dec 4.


The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.

de Jager H, Suleman F.

Int J Clin Pharm. 2019 Feb;41(1):81-87. doi: 10.1007/s11096-018-0758-x. Epub 2018 Nov 26.


Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.

Capoulade R, Yeang C, Chan KL, Pibarot P, Tsimikas S.

JAMA Cardiol. 2018 Dec 1;3(12):1212-1217. doi: 10.1001/jamacardio.2018.3798.


Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury.

Zhang J, Guo Y, Jin Q, Bian L, Lin P.

Drug Des Devel Ther. 2018 Oct 31;12:3685-3690. doi: 10.2147/DDDT.S178020. eCollection 2018.


Transfer of rosuvastatin into breast milk: liquid chromatography-mass spectrometry methodology and clinical recommendations.

Lwin EMP, Leggett C, Ritchie U, Gerber C, Song Y, Hague W, Turner S, Upton R, Garg S.

Drug Des Devel Ther. 2018 Oct 29;12:3645-3651. doi: 10.2147/DDDT.S184053. eCollection 2018.


Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects.

Kang WY, Seong SJ, Ohk B, Gwon MR, Kim BK, Cho S, Shim WS, Lee KT, Kim EH, Yang DH, Lee HW, Yoon YR.

Drug Des Devel Ther. 2018 Oct 26;12:3607-3615. doi: 10.2147/DDDT.S161917. eCollection 2018.


Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis.

Liping Z, Xiufang L, Tao Y, Baomin Z, Houshuai T.

Pak J Pharm Sci. 2018 Sep;31(5(Special)):2203-2208.


Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.

Akimoto H, Negishi A, Oshima S, Okita M, Numajiri S, Inoue N, Ohshima S, Kobayashi D.

Pharmacol Res Perspect. 2018 Nov 7;6(6):e00439. doi: 10.1002/prp2.439. eCollection 2018 Dec.


Mesenchymal stem cells associated with chitosan scaffolds loaded with rosuvastatin to improve wound healing.

Maged A, Abdelkhalek AA, Mahmoud AA, Salah S, Ammar MM, Ghorab MM.

Eur J Pharm Sci. 2019 Jan 15;127:185-198. doi: 10.1016/j.ejps.2018.11.002. Epub 2018 Nov 6.


Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.

Guedeney P, Baber U, Claessen B, Aquino M, Camaj A, Sorrentino S, Vogel B, Farhan S, Faggioni M, Chandrasekhar J, Kalkman DN, Kovacic JC, Sweeny J, Barman N, Moreno P, Vijay P, Shah S, Dangas G, Kini A, Sharma S, Mehran R.

Am Heart J. 2019 Jan;207:10-18. doi: 10.1016/j.ahj.2018.09.001. Epub 2018 Sep 12.


Supplemental Content

Loading ...
Support Center